ArticleProceedings of the National Academy of Sciences of the United States of America2021

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.

Itziar Ibarlucea-Benitez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.